Phase III Trial Tests Blood-Based MRD Monitoring to Spare Breast Cancer Patients CDK4/6 Inhibitor Toxicity
The new global phase III AFT-70 NAVIGATE trial will test whether ultrasensitive Signatera MRD blood monitoring can safely guide CDK4/6 ...
Tag: Signatera
POPULAR NEWS
-
Alloys That Shrink Their Own Grains: New PIX Mechanism Refines Metals With Heat Alone
-
Endurance Exercise Reshapes the Liver in Males and Females Through Distinct Molecular Routes
-
Single Transcription Factor PU.1 Rapidly Converts Fibroblasts into Macrophage-Lineage Cells
-
New Scale Measures How Ready Nurse Educators Really Are for the AI Era